title: Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B.
abstract: Hepatitis B virus (HBV) genotypes were examined in HIV-infected patients with chronic and occult HBV infection. From a total population of 593 HIV-infected patients, 22 individuals (prevalence 3.7%) were found to be HBsAg while 72 (12.1%) were found to be anti-HBc alone. From them, 20 and 4 were HBV DNA positive, respectively. These last four patients are therefore considered to be HBV infected in an occult form. The genotypes could be determined in all 24 HBV-infected patients. HBV-A was the most common (20/24; 83.3%), followed by HBV-D (2/24; 8.3%) and HBV-F (1/24; 4.2%). The remaining sample exhibited mixed infection involving genotypes A and D as pure ones, thus also forming part of three intergenotypic recombinant forms exhibiting different mosaic S gene patterns. The sexual route of transmission was predominant among HBV genotype A-infected patients. Among the 24 HBV DNA-positive patients, point mutations related to lamivudine resistance were found in four strains. These viral strains showed a methionine-to-valine substitution at codon 204 (rtM204V) in association with an upstream B-domain change at rtL180M. Additionally, two of them exhibited the additional rtV173L mutation. The value of HBV molecular monitoring including both HBV viral genomic characterization and genotypic resistance profile in HIV-HBV-coinfected individuals is discussed.
authors.affiliation: Centro Nacional de Referencia para el SIDA, Departamento de Microbiología, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155-Piso 11 (1121) Buenos Aires, Argentina. quarleri@fmed.uba.ar
authors.forename: J
authors.initials: J
authors.lastname: Quarleri
authors.forename: F
authors.initials: F
authors.lastname: Moretti
authors.forename: M B
authors.initials: MB
authors.lastname: Bouzas
authors.forename: N
authors.initials: N
authors.lastname: Laufer
authors.forename: M Gómez
authors.initials: MG
authors.lastname: Carrillo
authors.forename: S Fernández
authors.initials: SF
authors.lastname: Giuliano
authors.forename: H
authors.initials: H
authors.lastname: Pérez
authors.forename: P
authors.initials: P
authors.lastname: Cahn
authors.forename: H
authors.initials: H
authors.lastname: Salomon
mesh_terms: D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000494:pharmacology*; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000145:classification / Q000187:drug effects / Q000235:genetics*; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009154:Mutation / Q000187:drug effects*; D010802:Phylogeny
chemical_list: D019380:Anti-HIV Agents; D006514:Hepatitis B Surface Antigens; D019259:Lamivudine